Jasper Therapeutics (NASDAQ:JSPR) Rating Reiterated by Evercore ISI

Jasper Therapeutics (NASDAQ:JSPR)‘s stock had its “outperform” rating restated by equities research analysts at Evercore ISI in a note issued to investors on Monday, Benzinga reports. They presently have a $65.00 price objective on the stock. Evercore ISI’s price target suggests a potential upside of 234.88% from the company’s previous close.

A number of other equities analysts have also commented on the stock. BTIG Research assumed coverage on shares of Jasper Therapeutics in a research report on Monday, July 8th. They issued a “buy” rating and a $90.00 price target on the stock. HC Wainwright reissued a “buy” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research report on Tuesday, August 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Jasper Therapeutics in a research report on Tuesday, June 18th. Stifel Nicolaus started coverage on shares of Jasper Therapeutics in a research report on Thursday, June 27th. They issued a “buy” rating and a $86.00 price target on the stock. Finally, Royal Bank of Canada lowered their price objective on shares of Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating on the stock in a research note on Wednesday, August 14th. Nine investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $73.43.

Jasper Therapeutics Stock Up 0.6 %

Jasper Therapeutics stock traded up $0.12 during mid-day trading on Monday, hitting $19.41. The company’s stock had a trading volume of 110,153 shares, compared to its average volume of 134,823. The stock has a market capitalization of $292.39 million, a P/E ratio of -3.42 and a beta of 2.21. Jasper Therapeutics has a twelve month low of $4.00 and a twelve month high of $31.01. The stock’s fifty day moving average price is $20.07 and its two-hundred day moving average price is $22.54.

Jasper Therapeutics (NASDAQ:JSPR) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.09) by $0.12. Equities analysts expect that Jasper Therapeutics will post -4.41 earnings per share for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Large investors have recently added to or reduced their stakes in the business. Opaleye Management Inc. bought a new position in Jasper Therapeutics during the 4th quarter worth $3,144,000. Kingdon Capital Management L.L.C. boosted its stake in shares of Jasper Therapeutics by 16.4% during the fourth quarter. Kingdon Capital Management L.L.C. now owns 3,540,000 shares of the company’s stock valued at $2,793,000 after purchasing an additional 500,000 shares in the last quarter. Monaco Asset Management SAM acquired a new position in shares of Jasper Therapeutics in the fourth quarter worth approximately $197,000. StemPoint Capital LP acquired a new position in shares of Jasper Therapeutics in the first quarter worth approximately $3,794,000. Finally, Ikarian Capital LLC acquired a new position in Jasper Therapeutics in the first quarter valued at approximately $3,088,000. Institutional investors own 79.85% of the company’s stock.

About Jasper Therapeutics

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.